



PATENT  
ATTORNEY DOCKET NO. 07039/073001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant : Elliott Richelson et al.

Art Unit: 1635

Serial No.: 08/953,269

Examiner: Sean McGarry

Filed : October 17, 1997

Title : USING POLYAMIDE NUCLEIC ACID OLIGOMERS TO  
ENGENDER A BIOLOGICAL RESPONSE

Assistant Commissioner for Patents  
Washington, DC 20231

DECLARATION UNDER 37 CFR §1.132 OF ELLIOTT RICHELSON

I, Elliott Richelson, declare as follows:

1. I am a citizen of the United States and presently live at 109 Teal Pointe Lane, Ponte Vedra Beach, FL 32082-1936.
2. I am presently employed by Mayo Foundation, and have been so employed since 1975.
3. I received a Doctor of Medicine Degree from Johns Hopkins University, School of Medicine, Baltimore, MD.
4. I am an inventor on the above-indicated patent application.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

October 26, 2000

Date of Deposit

Signature

Jill Huse

Typed or Printed Name of Person Signing Certificate

5. I have read the Examiner's Office Actions mailed September 13, 1999 and April 26, 2000, including the sections where the Examiner contends that neither the specification nor my previous Declaration provides any guidance or evidence of how the PNA oligomers were initially screened for their expected *in vivo* activity.

6. Neither I, my co-inventors, nor individuals under our supervision performed *in vivo* screening to identify neurotensin-1 receptor-specific PNA oligomers having *in vivo* activity prior to administering the NTR1-PNA oligomer to a mammal. The NTR1-PNA oligomer was the first PNA oligomer targeting the non-coding strand of rat neurotensin-1 receptor that I, my co-inventors, or individuals under our supervision, administered to a mammal. As described in the above-indicated patent application, a sequence specific biological response was detected after *in vivo* administration of the NTR1-PNA oligomer. In addition, neither I, my co-inventors, nor individuals under our supervision have established a cell culture screening method capable of identifying neurotensin-1 receptor-specific PNA oligomers having biological activity.

7. Neither I, my co-inventors, nor individuals under our supervision performed *in vivo* or cell culture screening to identify mu-1 morphine receptor-specific PNA oligomers having *in vivo* activity prior to administering the MU1R-PNA oligomer to a mammal. The MU1R-PNA oligomer was the first PNA oligomer targeting the non-coding strand of rat mu-1 morphine receptor that I, my co-inventors, or individuals under our supervision, administered to a mammal. As described in the above-indicated patent application, a sequence specific biological response was detected after *in vivo* administration of the MU1R-PNA oligomer.

8. Neither I, my co-inventors, nor individuals under our supervision performed *in vivo* or cell culture screening to identify rat dopamine transporter-specific PNA oligomers having *in vivo* activity prior to administering the antisense DAT-PNA oligomer described in the DAT manuscript (a scientific manuscript submitted for publication entitled "Altering behavioral responses and dopamine transporter protein with antisense peptide nucleic acids") to a mammal. The antisense DAT-PNA oligomer was the first PNA

oligomer targeting the non-coding strand of rat dopamine transporter that I, my co-inventors, or individuals under our supervision, administered to a mammal. As described in the DAT manuscript, a sequence specific biological response was detected after *in vivo* administration of the antisense DAT-PNA oligomer.

9. Neither I, my co-inventors, nor individuals under our supervision performed *in vivo* or cell culture screening to identify rat angiotensinogen-specific PNA oligomers having *in vivo* activity prior to administering the sense-angiotensinogen PNA oligomer described in the angiotensinogen manuscript (a scientific manuscript submitted for publication entitled "Peptide nucleic acids specifically cause antigene effects *in vivo* by systemic injection") to a mammal. The sense-angiotensinogen PNA oligomer was the first PNA oligomer targeting the coding strand of rat angiotensinogen that I, my co-inventors, or individuals under our supervision, administered to a mammal. As described in the angiotensinogen manuscript, a sequence specific biological response was detected after *in vivo* administration of the sense-angiotensinogen PNA oligomer.

10. I understand that the Examiner, during a telephonic interview with Patrick Finn on March 16, 2000, indicated that the experiment presented in Example 3 of WO 99/20643 should be repeated using a PNA control. Individuals under my supervision conducted experiments using the SERT PNA described in Example 3 of WO 99/20643 and a control PNA oligomer. The control PNA oligomer had a scrambled sequence with respect to that of the SERT PNA. No statistically significant difference between SERT PNA-treated animals and control PNA-treated animals was detected when behavioral activity was measured. In addition, no statistically significant difference between the levels of serotonin transporter protein measured in the SERT PNA-treated animals and control PNA-treated animals was detected.

11. Individuals under my supervision conducted two experiments using a PNA oligomer targeting the coding strand of rat dopamine D2 receptor (sense DOP-PNA). In each experiment, animals treated with the sense DOP-PNA exhibited significantly more catalepsy than animals treated with saline. The level of dopamine D2 receptor protein

was measured in each experiment. In one experiment, animals treated with the sense DOP-PNA exhibited a significant reduction in the level of dopamine D2 receptor protein measured. In the other experiment, no statistically significant difference was detected in the levels of dopamine D2 receptor protein measured. In a separate experiment, a PNA oligomer targeting the non-coding strand of rat dopamine D2 receptor (antisense DOP-PNA) was administered to animals. In that experiment, animals treated with antisense DOP-PNA exhibited significantly more catalepsy than animals treated with saline. The levels of dopamine D2 receptor protein were not measured in this experiment. The sense DOP-PNA oligomer was the first PNA oligomer targeting the coding strand of rat dopamine D2 receptor that I, my co-inventors, or individuals under our supervision, administered to a mammal. The antisense DOP-PNA oligomer was the first PNA oligomer targeting the non-coding strand of rat dopamine D2 receptor that I, my co-inventors, or individuals under our supervision, administered to a mammal. Neither I, my co-inventors, nor individuals under our supervision performed *in vivo* or cell culture screening to identify dopamine D2 receptor-specific PNA oligomers having *in vivo* activity prior to administering the sense DOP-PNA and antisense DOP-PNA oligomers to a mammal.

12. Individuals under my supervision conducted experiments using a PNA oligomer targeting the coding strand of rat  $\beta$ -amyloid precursor protein (sense  $\beta$ -APP-PNA) and a control PNA oligomer similar to the sense  $\beta$ -APP-PNA with the exception that it contained a mismatch at every third nucleotide position (mismatch  $\beta$ -APP-PNA). The levels of A $\beta$  (1-40) and A $\beta$  (1-42) protein were measured in three experiments. In one of the three experiments, no statistically significant difference was detected between the levels of A $\beta$  (1-42) protein measured in sense  $\beta$ -APP-PNA-treated animals and mismatch  $\beta$ -APP-PNA-treated animals. In the other two experiments, however, animals treated with the sense  $\beta$ -APP-PNA exhibited a significantly lower level of A $\beta$  (1-42) protein when compared to the level exhibited in animals treated with the mismatch  $\beta$ -APP-PNA. In all three experiments, no difference was detected between the levels of A $\beta$  (1-40) protein measured for the two treatment groups. It is noted that a PNA oligomer targeting the non-coding strand of rat  $\beta$ -amyloid precursor protein (antisense  $\beta$ -APP-PNA) was

administered to animals. After administration, the levels of A $\beta$  (1-40) and A $\beta$  (1-42) protein were measured and compared to the levels measured in animals treated with saline. No statistically significant difference was detected, and no further experiments were conducted using the antisense  $\beta$ -APP-PNA. It also is noted that a second PNA oligomer targeting the coding strand of rat  $\beta$ -amyloid precursor protein (sense  $\beta$ -APP-PNA2) and a second PNA oligomer targeting the non-coding strand of rat  $\beta$ -amyloid precursor protein (antisense  $\beta$ -APP-PNA2) were administered to animals. After administration, the levels of A $\beta$  (1-40) and A $\beta$  (1-42) protein were measured and compared to the levels measured in animals treated with saline. No statistically significant difference was detected, and no further experiments were conducted using sense  $\beta$ -APP-PNA2 or antisense  $\beta$ -APP-PNA2. The sense  $\beta$ -APP-PNA and sense  $\beta$ -APP-PNA2 oligomers were the first two PNA oligomers targeting the coding strand of rat  $\beta$ -amyloid precursor protein that I, my co-inventors, or individuals under our supervision, administered to a mammal. The antisense  $\beta$ -APP-PNA and antisense  $\beta$ -APP-PNA2 oligomers were the first two PNA oligomers targeting the non-coding strand of rat  $\beta$ -amyloid precursor protein that I, my co-inventors, or individuals under our supervision, administered to a mammal. Neither I, my co-inventors, nor individuals under our supervision performed *in vivo* or cell culture screening to identify rat  $\beta$ -amyloid precursor protein-specific PNA oligomers having *in vivo* activity prior to administering the antisense  $\beta$ -APP-PNA, antisense  $\beta$ -APP-PNA2, sense  $\beta$ -APP-PNA, and sense  $\beta$ -APP-PNA2 oligomers to a mammal.

13. Individuals under my supervision conducted one experiment using a PNA oligomer targeting the coding strand of the protein component of human telomerase (sense TEL-PNA), a control PNA oligomer similar to sense TEL-PNA with the exception that it contained a mismatch at every third nucleotide position (mismatch TEL-PNA), and the PNA oligomer designated MUIR-PNA in the above-identified patent application. In this experiment, animals treated with the sense TEL-PNA exhibited significantly less tumor growth than animals treated with either the mismatch TEL-PNA or the MUIR-PNA. In a separate experiment, tumors from animals treated with the sense TEL-PNA

exhibited a significantly lower level of telomerase activity when compared to the level measured in tumors from animals treated with saline. Telomerase activity experiments were not performed using the mismatch TEL-PNA or MU1R-PNA controls. The sense TEL-PNA oligomer was the first PNA oligomer targeting the coding strand of the protein component of human telomerase that I, my co-inventors, or individuals under our supervision, administered to a mammal. Neither I, my co-inventors, nor individuals under our supervision performed *in vivo* or cell culture screening to identify human telomerase, protein component-specific PNA oligomers having *in vivo* activity prior to administering the sense TEL-PNA oligomer to a mammal.

14. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant patent application or any patent issuing thereon.

Dated: 10/26/2000

Elliott Richelson  
Elliott Richelson

STATE OF FLORIDA )

COUNTY OF Duval )

ss.

Before me this 26th day of October, 2000, personally appeared Elliott Richelson known to me to be the person whose name is subscribed to the foregoing Declaration, and acknowledged that he executed the same as his free act and deed for the purposes therein contained.

Beth Marten  
Notary Public

60024884.doc

